162 related articles for article (PubMed ID: 35743167)
1. Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents.
Bašová P; Paszeková H; Minařík L; Dluhošová M; Burda P; Stopka T
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743167
[TBL] [Abstract][Full Text] [Related]
2. The PU.1-Modulated MicroRNA-22 Is a Regulator of Monocyte/Macrophage Differentiation and Acute Myeloid Leukemia.
Shen C; Chen MT; Zhang XH; Yin XL; Ning HM; Su R; Lin HS; Song L; Wang F; Ma YN; Zhao HL; Yu J; Zhang JW
PLoS Genet; 2016 Sep; 12(9):e1006259. PubMed ID: 27617961
[TBL] [Abstract][Full Text] [Related]
3. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice.
Basova P; Pospisil V; Savvulidi F; Burda P; Vargova K; Stanek L; Dluhosova M; Kuzmova E; Jonasova A; Steidl U; Laslo P; Stopka T
Oncogene; 2014 Sep; 33(39):4735-45. PubMed ID: 24121269
[TBL] [Abstract][Full Text] [Related]
4. GATA-1 Inhibits PU.1 Gene via DNA and Histone H3K9 Methylation of Its Distal Enhancer in Erythroleukemia.
Burda P; Vargova J; Curik N; Salek C; Papadopoulos GL; Strouboulis J; Stopka T
PLoS One; 2016; 11(3):e0152234. PubMed ID: 27010793
[TBL] [Abstract][Full Text] [Related]
5. Vav1 is necessary for PU.1 mediated upmodulation of miR-29b in acute myeloid leukaemia-derived cells.
Vezzali F; Grassilli S; Lambertini E; Brugnoli F; Patergnani S; Nika E; Piva R; Pinton P; Capitani S; Bertagnolo V
J Cell Mol Med; 2018 Jun; 22(6):3149-3158. PubMed ID: 29532991
[TBL] [Abstract][Full Text] [Related]
6. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.
Gerloff D; Grundler R; Wurm AA; Bräuer-Hartmann D; Katzerke C; Hartmann JU; Madan V; Müller-Tidow C; Duyster J; Tenen DG; Niederwieser D; Behre G
Leukemia; 2015 Mar; 29(3):535-47. PubMed ID: 25092144
[TBL] [Abstract][Full Text] [Related]
7. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells.
Steidl U; Rosenbauer F; Verhaak RG; Gu X; Ebralidze A; Otu HH; Klippel S; Steidl C; Bruns I; Costa DB; Wagner K; Aivado M; Kobbe G; Valk PJ; Passegué E; Libermann TA; Delwel R; Tenen DG
Nat Genet; 2006 Nov; 38(11):1269-77. PubMed ID: 17041602
[TBL] [Abstract][Full Text] [Related]
8. A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report.
Grassilli S; Nika E; Lambertini E; Brugnoli F; Piva R; Capitani S; Bertagnolo V
Cell Oncol (Dordr); 2016 Oct; 39(5):483-489. PubMed ID: 27480083
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of Notch-1 expression decreases PU.1-mediated myeloid differentiation signaling in acute myeloid leukemia.
Chen PM; Yen CC; Wang WS; Lin YJ; Chu CJ; Chiou TJ; Liu JH; Yang MH
Int J Oncol; 2008 Jun; 32(6):1335-41. PubMed ID: 18497996
[TBL] [Abstract][Full Text] [Related]
10. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
Vangala RK; Heiss-Neumann MS; Rangatia JS; Singh SM; Schoch C; Tenen DG; Hiddemann W; Behre G
Blood; 2003 Jan; 101(1):270-7. PubMed ID: 12393465
[TBL] [Abstract][Full Text] [Related]
11. CircSPI1 acts as an oncogene in acute myeloid leukemia through antagonizing SPI1 and interacting with microRNAs.
Wang X; Jin P; Zhang Y; Wang K
Cell Death Dis; 2021 Mar; 12(4):297. PubMed ID: 33741901
[TBL] [Abstract][Full Text] [Related]
12. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
Curik N; Burda P; Vargova K; Pospisil V; Belickova M; Vlckova P; Savvulidi F; Necas E; Hajkova H; Haskovec C; Cermak J; Krivjanska M; Trneny M; Laslo P; Jonasova A; Stopka T
Leukemia; 2012 Aug; 26(8):1804-11. PubMed ID: 22343522
[TBL] [Abstract][Full Text] [Related]
13. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression.
Mueller BU; Pabst T; Fos J; Petkovic V; Fey MF; Asou N; Buergi U; Tenen DG
Blood; 2006 Apr; 107(8):3330-8. PubMed ID: 16352814
[TBL] [Abstract][Full Text] [Related]
14. A somatic mutation of GFI1B identified in leukemia alters cell fate via a SPI1 (PU.1) centered genetic regulatory network.
Anguita E; Gupta R; Olariu V; Valk PJ; Peterson C; Delwel R; Enver T
Dev Biol; 2016 Mar; 411(2):277-286. PubMed ID: 26851695
[TBL] [Abstract][Full Text] [Related]
15. The actin-binding protein CORO1A is a novel PU.1 (SPI1)- and CEBPA-regulated gene with significantly lower expression in APL and CEBPA-mutated AML patients.
Federzoni EA; Humbert M; Valk PJ; Behre G; Leibundgut EO; Torbett BE; Fey MF; Tschan MP
Br J Haematol; 2013 Mar; 160(6):855-9. PubMed ID: 23252456
[No Abstract] [Full Text] [Related]
16. CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation.
Batliner J; Mancarelli MM; Jenal M; Reddy VA; Fey MF; Torbett BE; Tschan MP
Mol Immunol; 2011 Jan; 48(4):714-9. PubMed ID: 21094529
[TBL] [Abstract][Full Text] [Related]
17. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
Barth J; Abou-El-Ardat K; Dalic D; Kurrle N; Maier AM; Mohr S; Schütte J; Vassen L; Greve G; Schulz-Fincke J; Schmitt M; Tosic M; Metzger E; Bug G; Khandanpour C; Wagner SA; Lübbert M; Jung M; Serve H; Schüle R; Berg T
Leukemia; 2019 Jun; 33(6):1411-1426. PubMed ID: 30679800
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia.
Yang H; Liang H; Yan JS; Tao R; Hao SG; Ma LY
Int J Hematol; 2012 Jul; 96(1):65-73. PubMed ID: 22674382
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
20. PU.1: a crucial and versatile player in hematopoiesis and leukemia.
Kastner P; Chan S
Int J Biochem Cell Biol; 2008; 40(1):22-7. PubMed ID: 17374502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
